ALAMEDA, Calif.--(BUSINESS WIRE)--Embryome Sciences, Inc., a wholly owned subsidiary of BioTime, Inc., (OTCBB:BTIM) has acquired from Advanced Cell Technology, Inc. (“ACT”) an exclusive license to use “ACTCellerate™” embryonic stem cell technology and a bank of over 140 diverse progenitor cell lines derived using that technology.
